Initiator Pharma As Stock Net Income
| INIT Stock | 3.01 0.02 0.66% |
Initiator Pharma's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Initiator Stock price.
Initiator |
Initiator Pharma AS Company Net Income Analysis
Initiator Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Initiator Pharma Net Income | (21.06 M) |
Most of Initiator Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Initiator Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Initiator Pharma AS reported net income of (21.06 Million). This is much lower than that of the sector and significantly lower than that of the Biotechnology industry. The net income for all Sweden stocks is notably higher than that of the company.
Initiator Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Initiator Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Initiator Pharma could also be used in its relative valuation, which is a method of valuing Initiator Pharma by comparing valuation metrics of similar companies.Initiator Pharma is currently under evaluation in net income category among its peers.
Initiator Fundamentals
| Return On Equity | -1.05 | |||
| Return On Asset | -0.49 | |||
| Current Valuation | 256.25 M | |||
| Shares Outstanding | 52.36 M | |||
| Shares Owned By Institutions | 0.46 % | |||
| Price To Book | 5.64 X | |||
| Gross Profit | (21.63 M) | |||
| EBITDA | (23.06 M) | |||
| Net Income | (21.06 M) | |||
| Total Debt | 13.29 M | |||
| Book Value Per Share | 0.71 X | |||
| Cash Flow From Operations | (34.1 M) | |||
| Earnings Per Share | (0.79) X | |||
| Target Price | 18.29 | |||
| Beta | 0.76 | |||
| Market Capitalization | 319.34 M | |||
| Total Asset | 53.7 M | |||
| Z Score | 14.4 | |||
| Net Asset | 53.7 M |
About Initiator Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Initiator Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Initiator Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Initiator Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Initiator Stock Analysis
When running Initiator Pharma's price analysis, check to measure Initiator Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Initiator Pharma is operating at the current time. Most of Initiator Pharma's value examination focuses on studying past and present price action to predict the probability of Initiator Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Initiator Pharma's price. Additionally, you may evaluate how the addition of Initiator Pharma to your portfolios can decrease your overall portfolio volatility.